CiteAb

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™

Retrieved on: 
Wednesday, June 7, 2023

This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence.

Key Points: 
  • This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence.
  • "That's why our team at CST has rigorously tested every one of our IHC-validated antibodies to ensure their specificity and sensitivity in IHC assays."
  • "The CST products tested on COMET™ gave clear results, demonstrating the capability to produce the high-quality images needed to enable the next generation of spatial biology research."
  • "This partnership provides scientists with that same high level of confidence in antibody sensitivity, specificity, and availability when using Lunaphore's leading spatial biology platform."

JAGGAER Version 22.2 Tackles Real Business Challenges While Advancing the Company’s Autonomous Commerce Strategy

Retrieved on: 
Tuesday, July 19, 2022

Taken in their totality, they also move us closer to our vision of Autonomous Commerce, with solutions that are networked, intelligent, comprehensive and extensible, commented JAGGAER CEO Jim Bureau.

Key Points: 
  • Taken in their totality, they also move us closer to our vision of Autonomous Commerce, with solutions that are networked, intelligent, comprehensive and extensible, commented JAGGAER CEO Jim Bureau.
  • With this latest version JAGGAER has implemented seamless connectivity between the solutions.
  • Last but not least, V22.2 includes a number of important third-party integrations, which further accelerate the Autonomous Commerce strategy of being extensible.
  • JAGGAER is leading the Autonomous Commerce revolution, a self-governing B2B commerce experience between buyers, suppliers, things (IoT) and partners.

JAGGAER and CiteAb to Deliver Industry-Leading Biological Reagent Search and Management Solution

Retrieved on: 
Tuesday, May 17, 2022

The integrated solution will offer efficiency gains, cost savings and compliance improvements via JAGGAER Research Material Management (RMM), the industry-leading solution for acquiring and managing commercial reagents and lab supplies used in research.

Key Points: 
  • The integrated solution will offer efficiency gains, cost savings and compliance improvements via JAGGAER Research Material Management (RMM), the industry-leading solution for acquiring and managing commercial reagents and lab supplies used in research.
  • The integration of CiteAb data within JAGGAER RMM will be available in June 2022 to new and existing JAGGAER RMM customers.
  • JAGGAER RMM has long been the solution of choice for lab researchers looking for chemical reagents.
  • We are delighted that CiteAbs expertise in biological reagent search will be available to researchers who use JAGGAERs purchasing systems, said Dr. Andrew Chalmers, CEO of CiteAb.

Abcam the most awarded company at 2022 industry awards

Retrieved on: 
Friday, March 25, 2022

CAMBRIDGE, England, March 25, 2022 /PRNewswire/ -- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.   

Key Points: 
  • CAMBRIDGE, England, March 25, 2022 /PRNewswire/ -- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards , the highest of any participant evaluated this year.
  • This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.
  • First and foremost, Abcam was recognized for its initiatives to improve standards in the reagent industry.
  • All three awards demonstrate Abcam's commitment to continually improving scientific reproducibility in life sciences, which benefits the research community and society globally.

Abcam the most awarded company at 2022 industry awards

Retrieved on: 
Friday, March 25, 2022

CAMBRIDGE, England, March 25, 2022 /PRNewswire/ -- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.   

Key Points: 
  • CAMBRIDGE, England, March 25, 2022 /PRNewswire/ -- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards , the highest of any participant evaluated this year.
  • This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance discoveries and deliver faster breakthroughs.
  • First and foremost, Abcam was recognized for its initiatives to improve standards in the reagent industry.
  • All three awards demonstrate Abcam's commitment to continually improving scientific reproducibility in life sciences, which benefits the research community and society globally.